Ra Capital Management, L.P. Buys 61,523 Shares of Hemab Therapeutics (NASDAQ:COAG) Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was purchased at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the purchase, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. This trade represents a 0.96% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, June 15th, Ra Capital Management, L.P. bought 6,146 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.89 per share, with a total value of $152,973.94.
• On Wednesday, May 20th, Ra Capital Management, L.P. bought 996 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.94 per share, with a total value of $24,840.24.
• On Tuesday, May 19th, Ra Capital Management, L.P. purchased 3,802 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.97 per share, for a total transaction of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.90 per share, for a total transaction of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. bought 9,906 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The stock was bought at an average price of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Price Performance

NASDAQ:COAG opened at $29.24 on Friday. Hemab Therapeutics Holdings, Inc. has a 52-week low of $23.00 and a 52-week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on COAG shares. Evercore assumed coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective for the company. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. HC Wainwright assumed coverage on shares of Hemab Therapeutics in a research report on Wednesday. They set a “buy” rating and a $40.00 price target for the company. Finally, Jefferies Financial Group started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price target on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $41.40.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.